# A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

> **NCT02813798** · PHASE1 · COMPLETED · sponsor: **GlycoMimetics Incorporated** · enrollment: 28 (actual)

## Conditions studied

- Renal Impairment
- Healthy

## Interventions

- **DRUG:** Rivipansel

## Key facts

- **NCT ID:** NCT02813798
- **Lead sponsor:** GlycoMimetics Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2020-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02813798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02813798, "A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02813798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*